Clinical trial
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
NCT02406729 · Butantan Institute, Other · Active, not recruiting
Key facts
| NCT number | NCT02406729 |
|---|---|
| Title | Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine |
| Official title | Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the Dengue 1, 2, 3, 4 (Attenuated) Vaccine From Instituto Butantan |
| Lead sponsor | Butantan Institute, Other |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dengue |
| Intervention type | Biological, Other |
| Interventions | Dengue 1, 2, 3, 4 (attenuated) vaccine, Placebo |
| Enrollment | 16,935 |
| Start date | Feb 22, 2016 |
| Primary completion | Jul 13, 2021 |
| Completion | Nov 1, 2024 |
| First posted | Apr 2, 2015 |
| Last update posted | Feb 15, 2024 |
| Countries | Brazil |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: